An update on the relevance of vaccine research for the treatment of metastatic melanoma.

Melanoma Manag

Chief Medical Officer, AIVITA Biomedical, Inc; Clinical Professor of Medicine, University of California Irvine, Irvine, CA 92612, USA.

Published: December 2017

Signal transduction inhibitors and anticheckpoint antibodies have significantly improved survival for metastatic melanoma patients, but most still die within 5 years. Vaccine approaches to induce immunity to well-characterized melanoma-associated antigens, or to antigens expressed on allogeneic tumor cell lines, have not resulted in approved agents. Despite the limitations associated with the immunosuppressive tumor microenvironment, there now is one intralesional autologous vaccine approved for patients who have primarily soft-tissue metastases. There is continued interest in patient-specific vaccines, especially dendritic cell vaccines that utilize loading of autologous antigen, thus bypassing certain immunosuppressive cells and cytokines. Because of their mechanism of action and limited toxicity, they are potentially synergistic or additive to other antimelanoma therapies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094615PMC
http://dx.doi.org/10.2217/mmt-2017-0021DOI Listing

Publication Analysis

Top Keywords

metastatic melanoma
8
update relevance
4
relevance vaccine
4
vaccine treatment
4
treatment metastatic
4
melanoma signal
4
signal transduction
4
transduction inhibitors
4
inhibitors anticheckpoint
4
anticheckpoint antibodies
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!